OBJECTIVES: To evaluate the liver safety of raltegravir-including combinations in HIV/hepatitis C virus (HCV) co-infected patients. METHODS: Grade 3-4 transaminase elevations (TEs) and grade 4 total bilirubin elevations (TBEs) were assessed during 12 months in 108 HIV/HCV co-infected patients starting antiretroviral therapy including raltegravir in a retrospective cohort study. Furthermore, the relationship between baseline fibrosis and hepatotoxic events was determined. RESULTS: Eight patients (7.4%) developed grade 3 TEs and two (1.9%) patients showed grade 4 TEs. TBE grade 4 was detected in two (1.9%) patients. No patient permanently discontinued raltegravir because of hepatotoxic events. Of the patients with and without significant fibrosis, six (9.4%) and two (11.8%), respectively, showed grade 3-4 TEs (P = 0.769). Grade 3-4 TEs was observed in four (9.8%) patients in whom cirrhosis was ruled out, while none of the patients diagnosed with cirrhosis developed grade 3-4 TEs (P = 0.303). During the follow-up, the median (Q1-Q3) CD4 cell count increased from 257 (145-421) cells/mm(3) to 407 (213-587) cells/mm(3) (P < 0.0001) and the number of patients with an undetectable HIV viral load augmented from 33 (30.6%) to 73 (81.1%) (P = 0.002). CONCLUSIONS: Raltegravir-containing regimens are safe in HIV/HCV co-infected patients. The incidence of severe liver toxicity of raltegravir in these individuals is in the range of boosted protease inhibitors in clinical trials. The frequencies of grade 3-4 TEs and grade 4 TBEs were similar in patients receiving raltegravir with or without significant fibrosis or cirrhosis.
OBJECTIVES: To evaluate the liver safety of raltegravir-including combinations in HIV/hepatitis C virus (HCV) co-infectedpatients. METHODS: Grade 3-4 transaminase elevations (TEs) and grade 4 total bilirubin elevations (TBEs) were assessed during 12 months in 108 HIV/HCV co-infectedpatients starting antiretroviral therapy including raltegravir in a retrospective cohort study. Furthermore, the relationship between baseline fibrosis and hepatotoxic events was determined. RESULTS: Eight patients (7.4%) developed grade 3 TEs and two (1.9%) patients showed grade 4 TEs. TBE grade 4 was detected in two (1.9%) patients. No patient permanently discontinued raltegravir because of hepatotoxic events. Of the patients with and without significant fibrosis, six (9.4%) and two (11.8%), respectively, showed grade 3-4 TEs (P = 0.769). Grade 3-4 TEs was observed in four (9.8%) patients in whom cirrhosis was ruled out, while none of the patients diagnosed with cirrhosis developed grade 3-4 TEs (P = 0.303). During the follow-up, the median (Q1-Q3) CD4 cell count increased from 257 (145-421) cells/mm(3) to 407 (213-587) cells/mm(3) (P < 0.0001) and the number of patients with an undetectable HIV viral load augmented from 33 (30.6%) to 73 (81.1%) (P = 0.002). CONCLUSIONS:Raltegravir-containing regimens are safe in HIV/HCV co-infectedpatients. The incidence of severe liver toxicity of raltegravir in these individuals is in the range of boosted protease inhibitors in clinical trials. The frequencies of grade 3-4 TEs and grade 4 TBEs were similar in patients receiving raltegravir with or without significant fibrosis or cirrhosis.
Authors: Karin Neukam; Nuria Espinosa; Antonio Collado; Marcial Delgado-Fernández; Patricia Jiménez-Aguilar; Antonio Rivero-Juárez; Victor Hontañón-Antoñana; Ana Gómez-Berrocal; Josefa Ruiz-Morales; Dolores Merino; Ana Carrero; Francisco Téllez; María José Ríos; José Hernández-Quero; María de Lagarde-Sebastián; Inés Pérez-Camacho; Francisco Vera-Méndez; Juan Macías; Juan A Pineda Journal: PLoS One Date: 2016-05-19 Impact factor: 3.240
Authors: Karin Neukam; José A Mira; Antonio Collado; Antonio Rivero-Juárez; Patricia Monje-Agudo; Josefa Ruiz-Morales; María José Ríos; Dolores Merino; Francisco Téllez; Inés Pérez-Camacho; María Carmen Gálvez-Contreras; Antonio Rivero; Juan A Pineda Journal: PLoS One Date: 2016-02-05 Impact factor: 3.240